BioSpace News Archive

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the first quarter ended March 31, 2022.

Vicarious Surgical Inc. (“Vicarious Surgical” or the “Company”) (NYSE: RBOT, RBOT WS), a next-generation robotics technology company seeking to improve patient outcomes as well as both the cost and efficiency of surgical procedures, today announced financial results for the quarter ended March 31, 2022.

Quantum-Si Incorporated, a life sciences company commercializing single molecule protein sequencing, announced the appointment of Patrick Schneider, Ph.D., as President and Chief Operating Officer.

Arcus Biosciences, Inc. (NYSE:RCUS), today reported financial results for the first quarter ended March 31, 2022 and provided a pipeline update on its six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b receptor), HIF-2a and PD-1 across multiple common cancers.

Roger Dansey, M.D., Chief Medical Officer, Appointed Interim CEO The Board of Directors of Seagen Inc. announced that President, CEO and Chairman Clay Siegall, Ph.D. is on a leave of absence.

Myovant Sciences and Accord Healthcare, Ltd. announced that they have entered into an exclusive license agreement for Accord to commercialize relugolix for the treatment of advanced hormone-sensitive prostate cancer under the trade name ORGOVYX® in the European Economic Area, United Kingdom, Switzerland and Turkey, with the right of first negotiation if Myovant decides to enter into licensing arrangements in countries in the Middle East, Africa and India.

BIOLASE, Inc., the global leader in dental lasers, announced that Kenneth P. Yale, D.D.S., J.D. was newly elected to its Board of Directors, effective April 28, 2022.

Berlin-based digital health company Fosanis, the developer of Mika, Germany’s first prescription DTx for all oncological indications, closed a series A funding round of more than 10 million EUR.

Tango Therapeutics, Inc. announced that members of the management team are scheduled to participate in a fireside chat at the Guggenheim Synthetic Lethality Day 2022 on Monday, May 16 at 10:00AM ET.

Evox Therapeutics Ltd, a leading exosome therapeutics company, announced two oral presentations at the International Society for Cell & Gene Therapy 2022 Meeting, May 4 to 7, in San Francisco.